Fluorescence agents: Imaging biological activity in vivo
Quantitative Tomography: FMT 2005 Imaging System
news
 VisEn Announces New ProSense® 750 FAST  and Neutrophil Elastase  680 FAST Fluorescent Agents
New Imaging Agents Launched at European Molecular Imaging Meeting 2010
more
news
 VisEn Launches  New VivoTag® 645  Fluorescence Molecular  Imaging Label
more
events
 Upcoming Events  & Workshops
July 15:  Mount Sinai School of Medicine; Life Sciences Exhibit Event (LSE), New York, NY
July 30:  Biogen Idec/Novartis/MIT/Whitehead Institute; Life Sciences Exhibit Event (LSE), Cambridge,  MA
Sept. 8-11:  2010 World Molecular Imaging Congress (WMIC), Kyoto, Japan
Sept. 22:  Molecular Imaging: Bridging Academia and Looking Beyond (a meeting of the ISACB); Boston, MA
Nov 4-5:  Memphis BioImaging Symposium (MemBIS); Memphis TN
Nov 13-17:  American Heart Assocation Scientific Sessions 2010; Chicago, IL
more

VisEn is a leader in fluorescence imaging solutions from research through medicine.  VisEn's in vivo fluorescence imaging technologies, including its RED Fluorescence Agent Portfolio and its quantitative Fluorescence Molecular Tomography (FMTTM) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in imaging applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas